We urge governments to remove the COVID-19 mRNA products from the market,
due to the well-documented risk of myocardial damage, a risk that is strongest for younger males ( under 40 years old).
Independent Medical Alliance
Senior Fellow of Paediatric Cardiology, Dr. Kirk Milhoan
National News desk link
Myocarditis after SARS-CoV-2 infection and COVID-19 vaccination: Epidemiology, outcomes, and new perspectives
International Journal of Cardiovascular Research & Innovation (OPEN ACCESS)
https://cardiovascular-research-and-innovation.reseaprojournals.com/Articles/myocarditis-after-sars-cov-2-infection-and-covid-19-vaccination-epidemiology-outcomes-and-new-perspectives
Myocarditis, typically manifesting as myopericarditis,
is among the serious cardiac consequences observed over the course of the COVID-19 pandemic.
A comprehensive, evidence-based literature synthesis
Clinical trial data reanalyses
Post-marketing surveillance
Large observational studies
Epidemiological, clinical, and immunological perspectives
Phenomenon of myocarditis post SARS-CoV-2 infection versus COVID-19 vaccine-induced myocarditis.
Conclusions refute several claims
(1). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Omicron infections have caused more cases of myocarditis than the COVID-19 mRNA immunizations
Refuted
(2) mRNA vaccine-induced myocarditis is typically mild, transient, and rare, with no long-term sequelae
Refuted
(3) the risk-benefit calculus favors continued use of these products despite evidence of more iatrogenic (vaccine causes) cases
Refuted
Source